AstraZeneca strategically adjusts $1.4 billion to sell Anaquzolando and Bikaluan

AstraZeneca is selling two cancer drugsforeign media reported that astravanathing sold the rights to two cancer drugs in Europe, Africa and other countries to Juvis?the drug Arimidex and Casodex, which are mainly used to treat breast and prostate cancer, have lost patent protection in those areas and the company sold both drugs in the United States in 2017Juvis? is a specialist pharmaceutical company in France that intends to enter the oncology market through this dealThe company previously focused on the production and commercialization of cardiovascular, tumor and neuropsychiatric drugs, according to the datathe French pharmaceutical company has only 11 years of development, but has sold its own drugs in 75 countries, $181 million was paid in advance, while future sales or payments amounted to $17 million, or about $200 million ($1.4 billion), and last year Arimidex brought in $37 million for countries covered by the agreement, while Casodex brought in $24 million, AstraZeneca's Executive Vice President of Oncology, Dave Fredrickson, said: Arimidex and Casodex are important mature drugs for AstraZeneca, and the sale is part of AstraZeneca's strategy to reduce its mature drug portfolio and reallocate resources to develop new drug channelstwo drugs, domestic large varietiesdata show that anaquzole is a powerful, selective nonsteroidal aromatase inhibitor, used in postmenopausal women's advanced breast cancer treatment and early breast cancer auxiliary treatmentAnaquzol tablets have been used clinically for many years as a category B variety of the National List of Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drugs (2019 Edition)the original manufacturer of the variety is ANI Pharmaceutical Pharmaceuticals, which was approved for marketing in the United States in 1995According to Minet data, in 2018 China's public medical institutions terminal Anaquzol tablet sales of more than 1 billion yuan, of which AstraZeneca accounted for the largest proportion, as high as 89.72 percentin addition to AstraZeneca, Yangzijiang Pharmaceutical Group accounted for 7.94 percent, Chongqing Huabang Pharmaceuticals accounted for 1.62 percent, Zhejiang Haizheng Pharmaceuticals accounted for 0.51 percent, Zhejiang Wanyi Pharmaceuticals accounted for 0.21 percent2017, AZ sold its right to sell an aminep in the U.S., and in recent days sold rights in Europe, Africa and other countries, whether or not the Chinese market will be involved in the futureIn the past 10 years, the incidence of prostate cancer in China has increased rapidly, with the incidence of prostate cancer reaching about 9.8 per 100,000 people, with an average annual growth rate of 12.07%the market for end-of-life prostate cancer drugs in key provinces and cities in 2018 was RMB 5 billion, an increase of 18.91 percent year-on-year The main oral drugs commonly used in China include abitron tablets, bicaruamine tablets, fluorotamamine tablets, meldonium tablets, meldonium tablets, hexaneestrogen tablets, injections including dositarace, gosherrein, quprilin, and bright propylene in the anti-prostate cancer drug pattern shown in the figure below, picaluamine accounted for 8.21% (Photo Source: Minet) AstraZeneca, selling and selling recently, AstraZeneca has been frequently selling varieties and production lines in early December, AstraZeneca announced that it had agreed to sell Seroquel's business rights in the U.S and Canada for $35 million to Thegerman pharmaceutical company Cheplapharm Arzneimittel, where seroquel's patents expired AstraZeneca received a total of $815 million in advances in the sale In July , AstraZeneca sold its European interest in Atacand, a brand of heart failure and high blood pressure, to Cheplapharm, a German pharmaceutical company in May, AstraZeneca signed a $538 million deal with China's Greenleaf Pharmaceuticals for the mental illness drug Seroquel and the reprieve , Mark Mallon, AstraZeneca's executive vice president of global strategy, said one of the company's strategic goals is to continuously scale down non-core treatment areas and invest resources in three key franchises: oncology, cardiovascular, metabolic and respiratory diseases original title: 1.4 billion, AstraZeneca sells two drugs